Development of a salt drug with improved solubility: Ethionamide nitrate

Autor(es)

Diniz, Luan F. ; Carvalho, Jr., Paulo S. ; de Melo, Cristiane C. ; Ellena, Javier

• Tipo de documento: Artigo Científico
• Fonte: Journal of Molecular Structure; v. 1137, p. 119-125, JUN 5 2017.
• Citações Web of Science: 2

Resumo

To avoid drug resistance, an adequate tuberculosis treatment should include not only a first-line drug but also at least one second-line drug such as, for example, Ethionamide (ETH). However, the dissolution rate and oral absorption of ETH is highly limited by its low aqueous solubility. Considering that a salt is in general more soluble than its parent compound, herein we depicted a new supramolecular modification of ETH, an Ethionamide nitrate salt (ETHNO3). This salt is the first ETH structure that has been crystallized with four independent ionic pairs (ETH+NOT3-) in the asymmetric unit. In addition to the structural study, the salt formation was also identified on the FT-IR and FT-Raman spectra. The thermal behavior of ETHNO3 was also investigated here together with its solubility profile in three dissolution media (purified water, pH 4.0 and 7.0). (C) 2017 Elsevier B.V. All rights reserved. (AU)

• Processo FAPESP: 15/25694-0 - Obtenção, caracterização e avaliação de novas formas sólidas cristalinas de fármacos usados no tratamento da tuberculose
• Beneficiário: Luan Farinelli Diniz
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 12/05616-7 - Caracterização no estado sólido de fármacos de ação anti-convulsionantes e antidepressivos: Planejamento de novas formas cristalinas.
• Beneficiário: Paulo de Sousa Carvalho Júnior
• Modalidade de apoio: Bolsas no Brasil - Doutorado